SIC 2834 – Pharmaceutical Preparations
Valuation | |
---|---|
Market Cap ($M) | 819,813.65 |
Enterprise Value ($M) | 851,684.05 |
Book Value ($M) | 14,320.70 |
Book Value / Share | 15.94 |
Price / Book | 57.25 |
NCAV ($M) | -31,703.60 |
NCAV / Share | -35.30 |
Price / NCAV | -25.86 |
Profitability (mra) | |
---|---|
Return on Invested Capital (ROIC) | 0.21 |
Return on Assets (ROA) | 0.17 |
Return on Equity (ROE) | 0.94 |
Liquidity (mrq) | |
---|---|
Quick Ratio | 0.89 |
Current Ratio | 1.15 |
Balance Sheet (mrq) ($M) | |
---|---|
Current Assets | 32,739.70 |
Assets | 78,714.90 |
Liabilities | 64,443.30 |
Debt | n/a |
Equity | n/a |
Income Statement (mra) ($M) | |
---|---|
Revenue | 45,042.70 |
Operating Income | 17,040.00 |
Net Income | 10,590.00 |
Earnings Per Share Basic And Diluted | n/a |
Earnings Per Share Diluted | n/a |
Earnings Per Share Basic | n/a |
Cash Flow Statement (mra) ($M) | |
---|---|
Cash From Operations | 8,817.90 |
Cash from Investing | -9,301.50 |
Cash from Financing | 1,230.10 |
(click for more detail) |
File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
---|---|---|---|---|
13G/A | Pnc Financial Services Group, Inc. | 5.39 | -0.11 | |
13G/A | Lilly Endowment Inc | 10.20 | -2.88 | |
13G/A | Vanguard Group Inc | 7.54 | -2.49 |
Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
---|---|---|---|---|
(click for more detail) |
Date | Insider Trades | Code | Shares | Value |
---|---|---|---|---|
(click for more detail) |
Short Volume | |||
---|---|---|---|
Market Date | Short Volume | Total Volume | Short Volume Ratio |
543,841 | 4,114,711 | 13.22 | |
640,279 | 2,780,363 | 23.03 | |
547,834 | 2,305,839 | 23.76 | |
518,157 | 2,797,356 | 18.52 | |
(click for more detail) |
Similar Companies | |
---|---|
ELAN – Elanco Animal Health Incorporated | HYAC – Haymaker Acquisition Corp. 4 |
JNJ – Johnson & Johnson | MRK – Merck & Co., Inc. |
NUVB – Nuvation Bio Inc. |